FDA approves avastin for late-stage cervical cancer
the ONA take:
Genentech, Inc. has announced that the US Food and Drug Administration (FDA) has approved Avastin (bevacizumab) for the treatment of patients with late-stage cervical cancer that is persistent, recurrent, or metastatic.
Treatment with Avastin should be in combination with paclitaxel and cisplatin or paclitaxel and topotecan. Avastin is also approved to treat patients with glioblastoma multiforme, metastatic colorectal cancer, metastatic renal cell carcinoma, and non-squamous non-small cell lung cancer. For cervical cancer, Avastin should be given at a dose of 15 mg/kg intravenously every 3 weeks.
Overall survival for patients with cervical cancer treated with chemotherapy plus Avastin had an overall survival of 16.8 months versus 12.9 months if treated with chemotherapy alone.
Avastin blocks angiogenesis and endothelial cell proliferation by binding to VEGF and preventing the interaction of VEGF to its receptors. Patients treated with Avastin should be advised to undergo routine blood pressure screenings and notified of the increased risk of wound healing complications, arterial thromboembolic events, and gastrointestinal perforation.
The National Cancer Institute estimates that at least 12,300 women in the United States will be diagnosed with cervical cancer and 4,000 will die as a result of the disease.
The FDA has approved a new use against late-stage cervical cancer.
The Food and Drug Administration has approved Genentech's Avastin for a new use against late-stage cervical cancer, the seventh indication for the blockbuster biotech drug. The FDA approved the drug late Thursday for women with cervical cancer that is persistent, recurrent or has spread to other parts of the body.
The disease is usually caused by the human papillomavirus, which is spread through sexual contact and causes cells to become cancerous. The National Cancer Institute estimates that over 12,300 U.S. women will be diagnosed with cervical cancer this year and 4,000 will die from the disease.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|